A phase 1, double-blind, placebo-controlled, randomized, single ascending dose and multiple ascending dose study to assess the safety, tolerability, and pharmacokinetics of GHF-201 in healthy adult volunteers
This early-stage study is looking at a new potential medicine, GHF-201, for a condition called Adult Polyglucosan Body Disease (APBD). Researchers are giving different doses of the medicine, or a dummy medicine (placebo), to healthy adult volunteers. The main goal is to check if GHF-201 is safe and well-tolerated at various doses. They also want to understand how the body absorbs, uses, and gets rid of the medicine. This type of study, called a Phase 1 trial, is a crucial first step in developing new treatments. It helps scientists learn important information about new medicines before they are tested in people who have the condition, paving the way for future research into APBD.
At a glance
What is this study about?
This study is about a new medicine called GHF-201, which is being investigated as a potential treatment for Adult Polyglucosan Body Disease (APBD). APBD is a rare condition that affects the nervous system, leading to various symptoms over time. Because GHF-201 is very new, this is a 'Phase 1' study. This means it's one of the very first times this medicine is being given to people.
The main purpose of this study is to find out if GHF-201 is safe for people to take and how well their bodies handle it. Researchers will also be checking how the medicine moves through the body – for example, how much is absorbed, how long it stays in the system, and how the body gets rid of it. To do this, healthy adult volunteers will receive either the actual medicine or a placebo, which is a dummy medicine containing no active ingredient.
This study is designed to be 'double-blind,' meaning neither the volunteers nor the researchers will know who is receiving the actual medicine and who is receiving the placebo. This helps to make the results as fair and unbiased as possible. By carefully studying GHF-201 in healthy volunteers, scientists can gather important information that will help decide if it's safe and promising enough to be tested in people living with APBD in future studies.
Key takeaways
- This is an early-stage study (Phase 1) of a new medicine for Adult Polyglucosan Body Disease.
- It aims to check the safety and how the body handles the medicine in healthy adults.
- Volunteers will receive either the new medicine or a dummy medicine (placebo).
- Both single and multiple doses will be tested to understand different effects.
- Participation is voluntary, and you can withdraw at any time.
- This research helps pave the way for future treatments for a rare condition.
Who may be eligible?
To join this study, you need to be a healthy adult aged 18 or older. Both men and women can take part.
The study is looking for people who are in generally good health and don't have any major medical conditions. This is because it's the very first time this new medicine is being tested in humans, and the researchers want to make sure any effects they see are due to the medicine and not other health problems.
There might be other specific health checks or criteria that you need to meet, which the study team will explain in detail. It's always best to discuss your full medical history with the study doctors to see if you are a good fit.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Are you in generally good health?
- Do you not have Adult Polyglucosan Body Disease?
- Are you able to attend all required clinic visits?
What does participation involve?
If you decide to take part, you will be given either the new medicine (GHF-201) or a placebo (a dummy medicine). Neither you nor the study team will know which you are receiving. You will likely visit the clinic regularly for health checks, blood tests, and to make sure you are feeling well. Some visits might be longer than others, involving staying at the clinic for a short period after receiving the dose.
During your time in the study, you'll be carefully monitored for any changes in your health or any side effects. The study will involve different groups of volunteers receiving different doses – some will get a single dose, and others will get multiple doses over a period. The total time you'll be involved in the study, including all visits and follow-up, will be explained to you in detail by the study team.
Potential risks and benefits
Locations (1)
- —UnverifiedBulgaria
Common questions
What is Adult Polyglucosan Body Disease (APBD)?
APBD is a rare genetic condition that usually appears in adulthood. It affects the nervous system and can cause problems with movement, sensation, and bladder control.
Why are healthy volunteers needed for this study?
Because GHF-201 is a new medicine, researchers first need to understand how it affects healthy people. This helps them learn about its safety and how it works in the body before testing it in patients with APBD.
What does 'double-blind' mean?
It means that neither you (as a volunteer) nor the study doctors will know whether you are receiving the actual medicine (GHF-201) or a dummy medicine (placebo). This helps make the study results fair.
Will I get paid for taking part?
Some studies offer payment or cover travel expenses for your time and effort. This will be fully explained to you by the study team before you decide to join.
Can I leave the study at any time?
Yes, absolutely. Your participation is completely voluntary, and you can withdraw from the study at any point, for any reason, without needing to explain why, and it won't affect your future medical care.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.